 Connection
Kevin Lillehei to Antineoplastic Agents
This is a "connection" page, showing publications Kevin Lillehei has written about Antineoplastic Agents.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.438 |
|
|
|
-
Lillehei KO, Kalkanis SN, Liau LM, Mydland DE, Olson J, Paleologos NA, Ryken T, Johnson T, Scullin E. Rationale and design of the 500-patient, 3-year, and prospective Vigilant ObservatIon of GlIadeL WAfer ImplaNT registry. CNS Oncol. 2018 04; 7(2):CNS08.
Score: 0.281
-
Kong Q, Kleinschmidt-DeMasters BK, Lillehei KO. Intralesionally implanted cisplatin plus systemic carmustine for the treatment of brain tumor in rats. J Surg Oncol. 1998 Oct; 69(2):76-82.
Score: 0.074
-
Fields EC, Damek D, Gaspar LE, Liu AK, Kavanagh BD, Waziri A, Lillehei K, Chen C. Phase I dose escalation trial of vandetanib with fractionated radiosurgery in patients with recurrent malignant gliomas. Int J Radiat Oncol Biol Phys. 2012 Jan 01; 82(1):51-7.
Score: 0.043
-
Schwer AL, Damek DM, Kavanagh BD, Gaspar LE, Lillehei K, Stuhr K, Chen C. A phase I dose-escalation study of fractionated stereotactic radiosurgery in combination with gefitinib in patients with recurrent malignant gliomas. Int J Radiat Oncol Biol Phys. 2008 Mar 15; 70(4):993-1001.
Score: 0.035
-
Liu Y, Lillehei K, Cobb WN, Christians U, Ng KY. Overcoming MDR by ultrasound-induced hyperthermia and P-glycoprotein modulation. Biochem Biophys Res Commun. 2001 Nov 23; 289(1):62-8.
Score: 0.006
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|